Search Results

Medtronic's IN.PACT Clinical Program Presented at TCT

September 28, 2010—Medtronic, Inc. (Minneapolis, MN) announced the latest results from the In.Pact coronary drug-eluting balloon (DEB) clinical program that were presented at the Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium in Washington, DC.

Spectranetics Receives CE Mark Approval for AngioSculptX

August 10, 2016—The Spectranetics Corporation announced receipt of CE Mark approval for the AngioSculptX drug-coated percutaneous transluminal coronary angioplasty scoring balloon catheter.

Long-Term Results Published for PACCOCATH-ISR Trial

March 20, 2012—Long-term clinical follow-up, including the binary restenosis rate and major adverse cardiovascular events, of the PACCOCATH-ISR I and II (Treatment of In-Stent Restenosis by Paclitaxel-Coated Percutaneous Transluminal Coronary Angioplasty [PTCA] Balloons) trials have been published by Bruno Scheller, MD, et al in the Journal of the American College of Cardiology: Cardiovascular Interventions (2012;5:323–330).

AngioScore Begins FIH Study of Drug-Coated AngioSculpt Scoring Balloon Catheter

December 14, 2011—AngioScore, Inc. (Fremont, CA) announced the commencement of enrollment in the Drug-Coated AngioSculpt Scoring Balloon Catheter First-in-Human (FIH) study.

Enrollment Completed for First-in-Human Study of AngioScore's AngioSculpt

June 19, 2013—AngioScore, Inc. (Fremont, CA) announced the completion of enrollment in the PATENT-C first-in-human (FIH) study of the company's drug-coated AngioSculpt scoring balloon catheter.

Preliminary Results Presented for AngioScore's AngioSculpt Drug-Coated Scoring Balloon Catheter

November 12, 2013—AngioScore, Inc. (Fremont, CA) announced detailed preliminary clinical trial results from the PATENT-C first-in-human study of the company's drug-coated AngioSculpt scoring balloon catheter.

Medtronic Receives IDE Approval for Pivotal Trial of Prevail DCB

October 23, 2024—Medtronic announced that the FDA has granted investigational device exemption approval to initiate the pivotal clinical trial of the company’s Prevail coronary paclitaxel drug-coated balloon (DCB) for in-stent restenosis (ISR) and de novo small vessel disease.

CoreMedic Partners With InnoRa for Development of ChordArt TMVr Device

January 17, 2025—CoreMedic GmbH recently announced it has entered into a strategic partnership with InnoRa GmbH to accelerate the clinical development of its ChordArt transcatheter mitral valve repair (TMVr) device.

QT Vascular's Chocolate Heart DCB Shows Promise in FIH Study

January 7, 2016—QT Vascular Ltd. announced the initial acute and 30-day outcomes from the first-in-human (FIH) study of the Chocolate Heart drug-coated balloon in a group of 19 patients with de novo coronary disease.